Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Clin Kidney J ; 8(4): 368-73, 2015 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-26251701

RESUMO

Increasing evidence suggests that treatment with online post-dilution haemodiafiltration (HDF) improves clinical outcome in patients with end-stage kidney disease, if compared with haemodialysis (HD). Although the primary analyses of three large randomized controlled trials (RCTs) showed inconclusive results, post hoc analyses of these and previous observational studies comparing online post-dilution HDF with HD showed that the risk of overall and cardiovascular mortality is lowest in patients who are treated with high-volume HDF. As such, the magnitude of the convection volume seems crucial and can be considered as the 'dose' of HDF. In this narrative review, the relevance of high convection volume in online post-dilution HDF is discussed. In addition, we briefly touch upon some safety and cost issues.

2.
Clin Kidney J ; 8(2): 191-8, 2015 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-25815176

RESUMO

In post-dilution online haemodiafiltration (ol-HDF), a relationship has been demonstrated between the magnitude of the convection volume and survival. However, to achieve high convection volumes (>22 L per session) detailed notion of its determining factors is highly desirable. This manuscript summarizes practical problems and pitfalls that were encountered during the quest for high convection volumes. Specifically, it addresses issues such as type of vascular access, needles, blood flow rate, recirculation, filtration fraction, anticoagulation and dialysers. Finally, five of the main HDF systems in Europe are briefly described as far as HDF prescription and optimization of the convection volume is concerned.

3.
Blood Purif ; 37(3): 229-37, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24943743

RESUMO

BACKGROUND/AIMS: Sub-analyses of three large trials showed that hemodiafiltration (HDF) patients who achieved the highest convection volumes had the lowest mortality risk. The aims of this study were (1) to identify determinants of convection volume and (2) to assess whether differences exist between patients achieving high and low volumes. METHODS: HDF patients from the CONvective TRAnsport STudy (CONTRAST) with a complete dataset at 6 months (314 out of a total of 358) were included in this post hoc analysis. Determinants of convection volume were identified by regression analysis. RESULTS: Treatment time, blood flow rate, dialysis vintage, serum albumin and hematocrit were independently related. Neither vascular access nor dialyzer characteristics showed any relation with convection volume. Except for some variation in body size, patient characteristics did not differ across tertiles of convection volume. CONCLUSION: Treatment time and blood flow rate are major determinants of convection volume. Hence, its magnitude depends on center policy rather than individualized patient prescription.


Assuntos
Hemodiafiltração/métodos , Idoso , Velocidade do Fluxo Sanguíneo , Tamanho Corporal , Conjuntos de Dados como Assunto , Feminino , Hematócrito/métodos , Hemodiafiltração/efeitos adversos , Humanos , Masculino , Pessoa de Meia-Idade , Guias de Prática Clínica como Assunto , Albumina Sérica/metabolismo , Fatores de Tempo
4.
Semin Dial ; 27(2): 119-27, 2014 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-24738146

RESUMO

The general objective assigned to the European DIALysis (EUDIAL) Working Group by the European Renal Association ­ European Dialysis and Transplant Association (ERA-EDTA) was to enhance the quality of dialysis therapies in Europe in the broadest possible sense. Given the increasing interest in convective therapies, the Working Group has started by focusing on hemodiafiltration (HDF) therapies. A EUDIAL consensus conference was held in Paris on 13 October 2011 to discuss definitions, safety standards, clinical outcome and educational issues. Recently, the first report of the EUDIAL group was published, revisiting the definition, dose quantification, and safety of HDF. Since the meeting in Paris, new evidence has become available regarding the clinical benefits of HDF. This is the second report of the expert group in which the relation between HDF and clinical outcomes is systematically reviewed and analyzed, with emphasis on the relation between achieved convection volume and treatment effect.


Assuntos
Hemodiafiltração , Humanos , Ensaios Clínicos Controlados Aleatórios como Assunto , Resultado do Tratamento
5.
PLoS One ; 9(2): e84587, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24505249

RESUMO

BACKGROUND AND OBJECTIVES: Left ventricular mass (LVM) is known to be related to overall and cardiovascular mortality in end stage kidney disease (ESKD) patients. The aims of the present study are 1) to determine whether LVM is associated with mortality and various cardiovascular events and 2) to identify determinants of LVM including biomarkers of inflammation and fibrosis. DESIGN SETTING PARTICIPANTS & MEASUREMENTS: Analysis was performed with data of 327 ESKD patients, a subset from the CONvective TRAnsport STudy (CONTRAST). Echocardiography was performed at baseline. Cox regression analysis was used to assess the relation of LVM tertiles with clinical events. Multivariable linear regression models were used to identify factors associated with LVM. RESULTS: Median age was 65 (IQR: 54-73) years, 203 (61%) were male and median LVM was 227 (IQR: 183-279) grams. The risk of all-cause mortality (hazard ratio (HR) = 1.73, 95% CI: 1.11-2.99), cardiovascular death (HR = 3.66, 95% CI: 1.35-10.05) and sudden death (HR = 13.06; 95% CI: 6.60-107) was increased in the highest tertile (>260 grams) of LVM. In the multivariable analysis positive relations with LVM were found for male gender (B = 38.8±10.3), residual renal function (B = 17.9±8.0), phosphate binder therapy (B = 16.9±8.5), and an inverse relation for a previous kidney transplantation (B = -41.1±7.6) and albumin (B = -2.9±1.1). Interleukin-6 (Il-6), high-sensitivity C-reactive protein (hsCRP), hepcidin-25 and connective tissue growth factor (CTGF) were not related to LVM. CONCLUSION: We confirm the relation between a high LVM and outcome and expand the evidence for increased risk of sudden death. No relationship was found between LVM and markers of inflammation and fibrosis. TRIAL REGISTRATION: Controlled-Trials.com ISRCTN38365125.


Assuntos
Doenças Cardiovasculares , Ventrículos do Coração , Falência Renal Crônica , Modelos Biológicos , Diálise Renal , Função Ventricular Esquerda , Idoso , Doenças Cardiovasculares/diagnóstico por imagem , Doenças Cardiovasculares/mortalidade , Doenças Cardiovasculares/fisiopatologia , Doenças Cardiovasculares/terapia , Feminino , Seguimentos , Ventrículos do Coração/diagnóstico por imagem , Ventrículos do Coração/fisiopatologia , Humanos , Falência Renal Crônica/diagnóstico por imagem , Falência Renal Crônica/mortalidade , Falência Renal Crônica/fisiopatologia , Falência Renal Crônica/terapia , Masculino , Pessoa de Meia-Idade , Ultrassonografia
6.
Blood Purif ; 35 Suppl 1: 39-44, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23466377

RESUMO

The CONvective TRAnsport STudy (CONTRAST) is a large randomized controlled trial which compared on-line postdilution hemodiafiltration and low-flux hemodialysis in terms of mortality and cardiovascular events. This review summarizes and discusses currently available knowledge acquired by CONTRAST, including the main outcome, comparisons of hemodiafiltration to hemodialysis as well as studies performed in subgroups of CONTRAST.


Assuntos
Convecção , Hemodiafiltração , Doenças Cardiovasculares/etiologia , Doenças Cardiovasculares/mortalidade , Hemodiafiltração/efeitos adversos , Hemodiafiltração/economia , Hemodiafiltração/métodos , Humanos , Qualidade de Vida , Ensaios Clínicos Controlados Aleatórios como Assunto , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA